Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.
Authors
- Ping Xiang (ORCID: https://orcid.org/0000-0002-0870-8551)
- Lu Si (ORCID: https://orcid.org/0000-0002-2123-9761)
- Yujie Li
- Xinan Sheng (ORCID: https://orcid.org/0000-0001-9359-0975)
- Bixia Tang (ORCID: https://orcid.org/0000-0002-3458-461X)
- Yixun Liu
- Jun Guo (ORCID: https://orcid.org/0000-0002-7374-2465)
- Xiangrong Dai (ORCID: https://orcid.org/0000-0001-7242-1216)
- Rong Duan
- Xiaoyi Li (ORCID: https://orcid.org/0000-0002-1453-4359)
- Xuechun Hu
- Li Zhou (ORCID: https://orcid.org/0000-0002-9331-0600)
- Zhi Liu (ORCID: https://orcid.org/0000-0001-9785-9150)
- Juan Li (ORCID: https://orcid.org/0000-0001-8002-8991)
- Siming Li (ORCID: https://orcid.org/0000-0002-2879-2113)
- Jun Xiao (ORCID: https://orcid.org/0009-0001-8186-8156)
- Xiaohui Yu (ORCID: https://orcid.org/0000-0002-7381-9709)
- Xieqiao Yan (ORCID: https://orcid.org/0000-0002-1781-3193)
- Zhihong Chi (ORCID: https://orcid.org/0000-0001-6257-6775)
- Chuanliang Cui (ORCID: https://orcid.org/0000-0001-6455-0843)
Institutions
- University of Science and Technology of China (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1093/oncolo/oyae260
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72